Predible Health vs Recursion Pharmaceuticals

Recursion Pharmaceuticals has a disclosed valuation of $2.2B, while Predible Health's valuation is not publicly available, making a direct size comparison difficult. Recursion Pharmaceuticals employs 800 people.

Predible Health has raised $5M in disclosed funding across 0 known rounds. Recursion Pharmaceuticals's funding history is not publicly available.

Recursion Pharmaceuticals holds the higher Awaira Score at 65/100, compared to Predible Health's 50/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 15-point gap that reflects meaningful differences in scale or traction.

Predible Health was founded by Sanjoy Paul in 2017. Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Visit each company's profile on Awaira for a full founder biography.

Predible Health: Predible Health develops AI software for radiology and medical imaging analysis, with a focus on automated CT scan interpretation for lung nodule detection, COVID-19 assessment, and liver segmentation. The platform integrates with radiology information systems and PACS to provide AI-assisted second reads and quantitative measurements that reduce reporting time and flag critical findings for urgent review.\n\nThe company raised approximately $5M in Series A funding and has established clinical partnerships with hospital networks and diagnostic imaging centers across India. Predible Health received significant validation through its COVID-19 CT analysis tool, which was deployed during the pandemic to help overwhelmed radiology departments manage surge volumes.\n\nRadiology AI represents one of the most commercially mature segments of medical AI globally, with clear clinical workflows, measurable radiologist productivity benefits, and established reimbursement pathways emerging in developed markets. Predible Health's India-focused deployments position it as a domestic alternative to global radiology AI companies, with the advantage of deep integration knowledge in Indian hospital IT environments. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed.

Recursion Pharmaceuticals was founded first in 2013, giving it 4 years of additional market experience. Predible Health was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Predible Health has approximately 10-50 employees, while Recursion Pharmaceuticals has approximately 800. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Predible Health and Recursion Pharmaceuticals are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.